MOR/CPR

Analysis of acquired drug resistance

Human lung adenocarcinoma, drug-resistant

MOR/CPR has been developed by growing the parent line, MOR, in increasing concentrations of cisplatin. The cells are cross-resistant to melphalan but show little or no cross-resistance to other platinum compounds. Cisplatin accumulation has been found to be reduced compared to the parent line.

RPMI 1640 + 2mM Glutamine + 1μg/ml cisplatin + 10% Foetal Bovine Serum (FBS).

Split subconfluent cultures (70-80%) 1:2 to 1:4 seeding at 2-4 x 10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C. It is recommended to culture the cells without drug after resuscitation until the first passage. These cells produce a

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to culturecollections@ukhsa.gov.uk.